TrialBMC medicine2026

Anti-IL-4Rα antibody SHR-1819 for moderate-to-severe atopic dermatitis: a randomized phase 2 study.

Chaoying Gu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.